A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs XR Manufactured At Two Different Sites.
Status:
Completed
Trial end date:
2007-05-02
Target enrollment:
Participant gender:
Summary
The present pharmacokinetic study is designed to compare bioavailability and assess
bioequivalence of two Rosiglitazone XR formulations produced at two different sites.Both
formulations will be tested in fasting healthy volunteers